Bank of America Begins Coverage on Alto Neuroscience (NYSE:ANRO)

Research analysts at Bank of America initiated coverage on shares of Alto Neuroscience (NYSE:ANRO) in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $35.00 price target on the stock. Bank of America‘s price objective points to a potential upside of 38.64% from the stock’s previous close.

Several other research analysts also recently commented on ANRO. Weiss Ratings upgraded Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. JonesTrading reduced their price target on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. Chardan Capital restated a “buy” rating and set a $30.00 price target on shares of Alto Neuroscience in a report on Wednesday, April 22nd. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Alto Neuroscience in a report on Thursday, April 2nd. Finally, Robert W. Baird reduced their price target on Alto Neuroscience from $41.00 to $38.00 and set an “outperform” rating on the stock in a report on Thursday, April 2nd. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $35.13.

Alto Neuroscience Stock Up 1.2%

ANRO opened at $25.25 on Tuesday. The company has a market cap of $806.48 million, a P/E ratio of -11.58 and a beta of 1.62. The business’s 50-day moving average price is $22.40 and its 200-day moving average price is $17.61. The company has a current ratio of 15.69, a quick ratio of 15.69 and a debt-to-equity ratio of 0.12. Alto Neuroscience has a 12 month low of $2.12 and a 12 month high of $28.44.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.11. On average, equities analysts expect that Alto Neuroscience will post -2.48 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. purchased a new position in shares of Alto Neuroscience during the 1st quarter worth approximately $67,000. AQR Capital Management LLC purchased a new position in shares of Alto Neuroscience during the 1st quarter worth approximately $52,000. Marshall Wace LLP grew its holdings in shares of Alto Neuroscience by 9.9% during the 2nd quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock worth $2,062,000 after acquiring an additional 84,417 shares during the period. Jane Street Group LLC purchased a new position in shares of Alto Neuroscience during the 2nd quarter worth approximately $240,000. Finally, Bridgeway Capital Management LLC grew its holdings in shares of Alto Neuroscience by 85.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after acquiring an additional 25,000 shares during the period.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.